![中国临床肿瘤学会(CSCO)恶性血液病诊疗指南·2020](https://wfqqreader-1252317822.image.myqcloud.com/cover/547/33145547/b_33145547.jpg)
上QQ阅读APP看书,第一时间看更新
2.5 治疗
2.5.1 诱导缓解治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image141.jpg?sign=1739286997-mjvd0h5VIYTnhxGW5NSHvvLXLx1kTxkB-0-445b92ed14f7ef945a610c7be9e434fa)
所有急性髓系白血病患者,可以参加临床研究的情况下,均建议首选参加临床研究。在没有临床研究的情况下,可以参照下述建议进行治疗。本章节为年龄<60岁成人患者。
2.5.2 诱导治疗后检测
诱导治疗过程中,建议在骨髓抑制期(停化疗后第7~14天左右)、恢复期(停化疗后第21~28天左右)复查骨髓。根据骨髓抑制期、血象恢复期的骨髓情况进行治疗调整。
(1)标准剂量Ara-C诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image142.jpg?sign=1739286997-Sl9ZgEZph1ETgUjmLOIL2b4cejQQh3zO-0-c1243aaaf6bcbc41181d5daca85f2a34)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image143.jpg?sign=1739286997-futTFj659lDELujif3cSOYVdX56yRq7k-0-b1fef7e4a69e1be72f31947225fc8a6a)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image144.jpg?sign=1739286997-t3sdqsMCe3SDkVAfRkJkpwet6YGkxueu-0-ee55ea01192a3f0b18b50536274729e0)
(2)含中大剂量Ara-C方案的诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image145.jpg?sign=1739286997-4t6r6cnMe79CrtFfTEim9TVs9bPGrQDL-0-a1e561df894364ed3df0301fcaacc0b3)
2.5.3 AML完全缓解后治疗的选择
按遗传学预后危险度分组治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image146.jpg?sign=1739286997-Yxi19xOSkjgzmpT0FxSZBlImuVQO5UZs-0-f639c211d6b69eb8a0cc4f99d7c76626)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image147.jpg?sign=1739286997-cjLLMmuRyzRapJH521Zowf4iFMQNIE84-0-27de44e50dc24e037549a9b36df88685)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image148.jpg?sign=1739286997-3WWLHuxAQgoLPqqCmE0a2Lr7PUu6Vuhe-0-03bb920936dbbd24efbe2170e1810b5f)